1.89
7.39%
+0.13
After Hours:
1.85
-0.04
-2.12%
Xeris Biopharma Holdings Inc stock is currently priced at $1.89, with a 24-hour trading volume of 2.13M.
It has seen a +7.39% increased in the last 24 hours and a -1.05% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.80 pivot point. If it approaches the $1.98 resistance level, significant changes may occur.
Previous Close:
$1.76
Open:
$1.81
24h Volume:
2.13M
Market Cap:
$280.20M
Revenue:
$163.91M
Net Income/Loss:
$-62.26M
P/E Ratio:
-3.6346
EPS:
-0.52
Net Cash Flow:
$-49.29M
1W Performance:
-0.26%
1M Performance:
-1.05%
6M Performance:
+16.67%
1Y Performance:
-34.83%
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
180 North LaSalle Street, Suite 1810, Chicago, IL
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-21-22 | Initiated | Jefferies | Buy |
Apr-28-22 | Initiated | Craig Hallum | Buy |
Nov-17-21 | Initiated | SVB Leerink | Outperform |
Oct-29-21 | Initiated | H.C. Wainwright | Buy |
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Feb-18-20 | Initiated | Piper Sandler | Overweight |
Jul-16-18 | Initiated | Jefferies | Buy |
Jul-16-18 | Initiated | Leerink Partners | Outperform |
Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
Zacks Investment Research
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Seeking Alpha
Why Xeris (XERS) Might Surprise This Earnings Season
Zacks Investment Research
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
Zacks Investment Research
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Xeris Biopharma Holdings Inc (XERS) Revenue 2024
XERS reported a revenue (TTM) of $163.91 million for the quarter ending December 31, 2023, a +48.68% rise year-over-year.
Xeris Biopharma Holdings Inc (XERS) Net Income 2024
XERS net income (TTM) was -$62.26 million for the quarter ending December 31, 2023, a +34.23% increase year-over-year.
Xeris Biopharma Holdings Inc (XERS) Cash Flow 2024
XERS recorded a free cash flow (TTM) of -$49.29 million for the quarter ending December 31, 2023, a +52.34% increase year-over-year.
Xeris Biopharma Holdings Inc (XERS) Earnings per Share 2024
XERS earnings per share (TTM) was -$0.44 for the quarter ending December 31, 2023, a +37.14% growth year-over-year.
About Xeris Biopharma Holdings Inc
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Cap:
|
Volume (24h):